Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 681 - 691 |
| Number of pages | 11 |
| Journal | AIDS Patient Care and STDs |
| Volume | 27 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 2013 |
Cite this
}
Antiretroviral Treatment Interruption and Loss to Follow-Up in Two HIV Cohorts in Australia and Asia: Implications for 'Test and Treat' Prevention Strategy. / Guy, Rebecca; Wand, Handan; McManus, Hamish; Saphon, Vonthanak; Woolley, Ian John; Honda, Miwako; Read, Tim; Sirisanthana, Thira; Zhou, Julian.
In: AIDS Patient Care and STDs, Vol. 27, No. 12, 2013, p. 681 - 691.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Antiretroviral Treatment Interruption and Loss to Follow-Up in Two HIV Cohorts in Australia and Asia: Implications for 'Test and Treat' Prevention Strategy
AU - Guy, Rebecca
AU - Wand, Handan
AU - McManus, Hamish
AU - Saphon, Vonthanak
AU - Woolley, Ian John
AU - Honda, Miwako
AU - Read, Tim
AU - Sirisanthana, Thira
AU - Zhou, Julian
PY - 2013
Y1 - 2013
N2 - Abstract Both antiretroviral treatment interruption (TI) and cessation have been strongly discouraged since 2006. We describe the incidence, duration, and risk factors for TI and loss-to-follow-up (LTFU) rates across 13 countries. All 4689 adults (76 men) in two large HIV cohorts in Australia and Asia commencing combination antiretroviral therapy (ART) to March 2010 were included. TI was defined by ART cessation >30 days, then recommencement, and loss to follow-up (LTFU) by no visit since 31 March 2009 and no record of death. Survival analysis and Poisson regression methods were used. With median follow-up of 4.4 years [interquartile range (IQR):2.1-6.5], TI incidence was 6.7 per 100 person years (PY) (95 CI:6.1-7.3) pre-2006, falling to 2.0 (95 CI:1.7-2.2) from 2006 (p/=7 pills per day; and ART with food restrictions (fasting or with food). In conclusion, since 2006, 7.8 of patients had significant time off treatment, which has the potential to compromise any test and treat policy as during the interruption viral load will rebound and increase the risk of transmission.
AB - Abstract Both antiretroviral treatment interruption (TI) and cessation have been strongly discouraged since 2006. We describe the incidence, duration, and risk factors for TI and loss-to-follow-up (LTFU) rates across 13 countries. All 4689 adults (76 men) in two large HIV cohorts in Australia and Asia commencing combination antiretroviral therapy (ART) to March 2010 were included. TI was defined by ART cessation >30 days, then recommencement, and loss to follow-up (LTFU) by no visit since 31 March 2009 and no record of death. Survival analysis and Poisson regression methods were used. With median follow-up of 4.4 years [interquartile range (IQR):2.1-6.5], TI incidence was 6.7 per 100 person years (PY) (95 CI:6.1-7.3) pre-2006, falling to 2.0 (95 CI:1.7-2.2) from 2006 (p/=7 pills per day; and ART with food restrictions (fasting or with food). In conclusion, since 2006, 7.8 of patients had significant time off treatment, which has the potential to compromise any test and treat policy as during the interruption viral load will rebound and increase the risk of transmission.
UR - http://online.liebertpub.com/doi/pdf/10.1089/apc.2012.0439
U2 - 10.1089/apc.2012.0439
DO - 10.1089/apc.2012.0439
M3 - Article
VL - 27
SP - 681
EP - 691
JO - AIDS Patient Care and STDs
JF - AIDS Patient Care and STDs
SN - 1087-2914
IS - 12
ER -